TrialJournal for immunotherapy of cancer2024

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.

Sandip P Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.